	Admission Form
Patient Details	CIDR Event ID (Official Use Only)
ease complete this form for pa	tients where COVID/Influenza/RSV was the primary or contributing cause of admissio
U. Please exclude incidental ca	ISES. Surname MRN
	y   m Gestational age at time of birth (weeks):   Sex: Female Male
DOB: Age: Age: Public Health Region of Residence	County of Residence     Country of Residence
Country of birth	Weight (kg) Height (cm) BMI
GP Name	Ethnicity Eircode
GP Telephone	GP Address
All information comple	ted on this form should relate to the patient's admission to THIS hospital, not referring hospital
Name hospital	
Date of hospital admission	Date of admission to ICU
Source of ICU admission: From wi	ithin this hospital
	Chine this hospital OR Control
Erom an	
	Nother hospital - ICU Name of other hospital
Clinical Details	
	9, Influenza or RSV) the primary or contributing cause of ICU admission?
Primary Contributing	
Please select organisms that apply	
SARS-CoV-2 (COVID-19)	nfluenza A (not subtyped) Influenza A (H1) pdm 2009
Influenza A (H3)	nfluenza B Respiratory syncytial virus (RSV)
Co-infected with invasive Group A Stre	ep (iGAS) Yes No Unknown
Was the infection determined to be he	ospital acquired? Yes No Unknown
Date of onset of symptoms	Date of diagnosis
Monoclonal Antibody (if notifying RS)	V)
Did the patient receive monoclonal ar	ntibody? Yes No Unknown Date of most recent dose
Monoclonal antibody type (if available	e) Nirsevimab Palivizumab Unknown
Does the patient require non-invasive admission?	mechanical ventilation (CPAP,BiPAP or HFNO) on Yes No Unknown
Does the patient require invasive mecl	hanical ventilation on admission? Yes No Unknown
Does the patient require ECMO?	
	Yes No Unknown

Signature \_\_\_\_

Paediatric Influenza, RSV and COVID-19 Admission Form - Part 1 (Page 1 of 3)

Date

ΡΤΟ

## Influenza, RSV and COVID-19 Enhanced Surveillance Critical Care Neonatal & Paediatric (0-14 years) Admission Form



Unknown

MRN

**Underlying medical conditions** 

Initials

DOB	

Yes

No

Does the case have any underlying medical conditions?	
Cardiovascular condition/treatment for Congenital Heart Disease	
Chronic renal disease	
Nephrotic syndrome	
Congenital Renal Disease	
Chronic liver disease	
Long term aspirin therapy	
Hypothyroidism	
Cancer/malignancy including haematological <sup>1</sup>	
Immunodeficiency/Immunosuppression	
Due to HIV	
Due to Solid Organ Transplantation	
Due to Haematopoietic Stem Cell Transplant (HSCT)	
Due to Therapy (chemotherapy, radiotherapy, high dose steroid,	
Immunomodulators, anti-TNF agents, etc see definitions pg3)	
Due to primary immunodeficiency (see definitions pg3)	
Due to inherited metabolic disorders	
Due to Asplenia / Splenic dysfunction	
Chronic respiratory disease including:	
Bronchiectasis	
Cystic fibrosis	
Asthma (requiring medication)	
Mild to Moderate	
Severe (uncontrolled despite proper medication and treatment)	
Chronic Neurological Disease	
Seizure Disorder	
Cerebral Palsy	
Spina Bifida	
Myotonic and Muscular Dystrophy	
Trisomy 21/ other developmental conditions	

**Diabetes mellitus** 

Type I

Type II

Other underlying medical conditions, please specify:

<sup>1</sup>Includes, leukaemia, lymphomas, blood dyscrasias or other malignant neoplasms affecting the bone marrow or lymphatic systems. **Please send Critical Care Admission Form to HPSC when patient is first admitted to ICU** Email: hpsc-data@hpsc.ie Fax: 01-8561299 Paediatric Influenza, RSV and COVID-19 Admission Form - Part 1 (Page 2 of 3)

Patient Details		Discharge For		
auent Details All information	n completed on ti	his form should relate to	the patient's current ICU adm	iission
Forename	Surname		CIDR Event ID	For HPSC use only
DOB	MRN			
Name Of Hospital				
Date of discharge from ICU		Length of stay in	ICU (days)	
Clinical complictaions				
Please tick all that apply	Yes No		Yes N	0
Apnoea		Hypoxemia		
Primary viral pneumonia		Myocarditis		<sup>1</sup> See AKI Definition on
Secondary bacterial pneumonia		Encephalitis		page 4
Acute respiratory distress syndrome		Croup		<sup>2</sup> See ICNARC definition on
Acute Kidney Injury <sup>1</sup>		Meningitis		page 4
Multiorgan failure <sup>2</sup>		Sepsis		
Bronchiolitis				
Treatment intervention				
Pressor dependence at any time	es No	Nebulisation Therapy	y in ICU	
CRRT/IHD		High flow nasal oxyg	en in ICU	
Hemofiltration/Plasmapheresis		Duration O <sup>2</sup> (days)		
Mechanical ventilation (in curren	t PICU/NICU i.e. a	lata should not include n	nechanical ventilation in othe	r hospitals)
Non-invasive advanced respiratory support	-	Yes No		. ,
CPAP ventilation			Duration CPAP ventilation (day	
BiPAP ventilation			Duration BiPAP ventilation (dag	ys)
nvasive mechanical ventilation		Yes No		
Conventional (including lung protective) mecha	nical ventilation		Duration conventional MV (day	s)
ECMO			Duration ECMO (days)	
Discharge Information				
Transferred from ICU to: Ward Or *Other refers to a different hospital If transferred to other ICU, please state name If patient transferred to a different hospital for E	her* Ward	HDU Other* HDI	J Other* ICU ECM	O abroad Died
Deaths				
1				
If died, date of death:	Yes		Not applic	able
Is COVID-19 a likely cause of death?	Yes	4 1-4	known Not applic Known Not applic	
Is influenza a likely cause of death?			nown Not applic	
Is RSV a likely cause of death?	Yes			
Comments				



**Discharge Form** 

CI Intensive Care Society of Ireland



## Definitions

## Acute Kidney Injury Use AKIN classification

Stage	Creatinine Cri	teria		Urine output criteria
1	Cr. x 1.5–2 fro	m baseline	or	<0.5 ml/kg/hr for 6 hours
2	Cr. x 2-3 fro	m baseline	or	<0.5 ml/kg/hr for 12 hours
3	Or	m baseline	or	< 0.3 ml/kg/hr for 24 hours or anuria for 12 hours or need for
Cr = 354 umol/l with an acute rise > 44 umol/l or need RRT			RRT	
Immuno	odeficiency/Immu	unosuppression		
<ul> <li>likely to be immunosuppressive. Adults and children =10kg: = 40 mg/day for mo 1 week, or=20 mg/day for 2 weeks or longer; Children &lt; 10 kg:2mg/kg/day for 2 or longer.</li> <li>Azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine, leflunomid methotrexate, mycophenolic acid preparations, sirolimus and tacrolimus, in add biologics, such as TNFa blocking agents (adalimumab, etanercept, infliximab), ar others including abatacept, anakinra, eculizumab, rituximab and tocilizumab.</li> </ul>			or longer; Children < 10 kg:2mg/kg/day for 2 weeks vclosporine, hydroxychloroquine, leflunomide, reparations, sirolimus and tacrolimus, in addition to ents (adalimumab, etanercept, infliximab), and a, eculizumab, rituximab and tocilizumab.	
Due to primary immunodeficiency XLA), Chronic/cyclic neutropoenia, Chronic gran mucocutaneous candidiasis (APECED syndrome) variable immunodeficiency (CVID) & other immu syndrome, Down syndrome, Fanconi's anaemia, combined immunodeficiency syndrome (SCID)			Chronic granulomatous disease (CGD), Chronic D syndrome), Complement deficiency, Common & other immunoglobulin deficiencies, DiGeorge ni's anaemia, Wiskott Aldrich Syndrome, Severe	

## Multiorgan failure

Using ICNARC definition

ICNARC define Level 3 care as patients requiring organ support for two or more organ systems, excluding gastrointestinal support.